DDInter147 DDInter122
Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation VEGFR inhibitors. Axitinib is an indazole derivative. It is most commonly marketed under the name Inlyta® and is available in oral formulations.
Artesunate is indicated for the initial treatment of severe malaria. The World Health Organization recommends artesunate as first line treatment for severe malaria. Artesunate was developed out of a need for a more hydrophilic derivative of [artemisinin]. Artesunate was granted FDA approval on 26 May 2020.
Axitinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lansoprazole
Axitinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sodium citrate
Axitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epirubicin
Axitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Netupitant
Axitinib {u} may lead to a major life threatening interaction when taken with {v} Atazanavir
Axitinib {u} may lead to a major life threatening interaction when taken with {v} Lomitapide
Axitinib may cause a minor interaction that can limit clinical effects when taken with Lansoprazole
Axitinib may cause a minor interaction that can limit clinical effects when taken with Sodium citrate
Axitinib may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin
Axitinib may cause a moderate interaction that could exacerbate diseases when taken with Netupitant
Axitinib may lead to a major life threatening interaction when taken with Atazanavir
Axitinib may lead to a major life threatening interaction when taken with Lomitapide